Eisai Declines Most in Four Months on Aricept Sales Prospects
Eisai Co., the maker of Aricept, the world’s best-selling treatment for Alzheimer’s disease, fell the most in four months in Tokyo trading on concern that efforts to maintain demand for the drug may not work.
Eisai slumped 2.8 percent to 3,105 yen on the Tokyo Stock Exchange at 12:47 p.m., the most since March 29. Aricept sales plunged 49 percent to 42 billion yen in the three months ended June 30, the Tokyo-based company said yesterday.
A company strategy to prevent patients being prescribed alternatives to Aricept and another best-selling Eisai medicine in the U.S. “appears likely to end in failure,” Credit Suisse AG analysts said in a report today.
To contact the reporter on this story: Kanoko Matsuyama in Tokyo at email@example.com
To contact the editor responsible for this story: Jason Gale at firstname.lastname@example.org
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.